Induced pluripotent stem cell derived allogeneic cellular therapies - RxCell

Alternative Names: Allogeneic cellular therapy - RxCell; iPSC-derived-cellular-therapies - RxCell

Latest Information Update: 07 Dec 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Institute of Molecular and Cell Biology; National University of Singapore; RxCell; Singapore Eye Research Institute
Class Induced pluripotent stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 Dec 2023 Preclinical trials in Age-related macular degeneration in USA (Parenteral)
05 Dec 2023 RxCell plans a phase I/IIa trial in age-related macular degeneration in USA (Parenteral)
26 Oct 2021 RxCell plans a first-in-human trial for Age-related macular degeneration in Singapore

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com